RFE Pharma Corp. was formed in December, 2004 from the merger of Somatocor Pharmaceuticals Inc., and RFE Pharma LLC. Somatocor was founded in April, 2001 by researcher and entrepreneur Dr. Gideon Shapiro to develop small molecule somatostatin receptor drugs as a "spin-out" of a program at Novartis Pharmaceuticals. RFE Pharma LLC was founded in August, 2004 by retinal specialist Dr. Alan Franklin and drug development expert Dr. Gary Robinson to provide a vehicle for the development of an in-licensed clinical candiadte drug, RFE-007. This merger of the two companies into RFE Pharma Corp. created a single Company with a product pipeline derived from in-licensed technologies. One technology suite was developed by Somatocor's founder, Dr. Gideon Shapiro, and provides for RFE Pharma's pipeline of somatostatin receptor agonist-based, small molecule clinical drug candidates for treating severe eye disease, pain, and cancer. The other technology provides for a clinical drug candidate that was brought into the newly merged Company by Drs. Alan Franklin and Gary Robinson through academic collaborations and ongoing in-licensing activities. The newly merged Company has a lead drug candiadte for the treatment of severe eye disease and cancer and a solid pipeline containing drug candidates for the treatment of proliferative eye disease, pain, and cancer. RFE Pharma believes it is well positioned to become a specialty pharmaceutical Company with two advanced drug candidates for the treatment of severe eye disease, and pipeline opportunities in cancer and pain. RFE Pharma Corp. is a privately held company.
Cogentus utilizes a capital-efficient business model that leverages its inventive, deeply-experienced internal and external professionals to systematically and rapidly identify, evaluate and develop unique combination prescription pharmaceutical products. The company's products derive from leads generated internally or via external sources based on licensing and/or corporate collaborations. Cogentus applies excellence to the elaboration of product concepts, the establishment of commercial and intellectual property strategies, and the design and execution of product development plans. The company's approach supports optimal probabilities of success and efficient product approvals.
Shire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceutical company with a strategic focus on meeting the needs of the specialist physician and currently focuses on developing projects and marketing products in the areas of central nervous system (CNS), gastrointestinal (GI), and renal diseases. Shire has operations in the world's key pharmaceutical markets (US, Canada, UK, France, Italy, Spain and Germany) as well as a specialist drug delivery unit in the US.
Mimetogen Pharmaceuticals is a venture-backed biotechnology company founded by Prof. H. Uri Saragovi and Dr. Garth Cumberlidge. The company is actively pursuing the development of novel small molecule compounds to treat small cell lung cancer and glaucoma. Both diseases represent very large unmet medical needs; the former indication having seen little or no improvement in survival rates over the last 30 years and the current treatment of the latter becoming more inadequate as life expectancy continues to rise.
Kanisa Pharmaceuticals, Inc., based in San Diego, CA, is an oncology-focused specialty pharmaceutical company employing a targeted approach to the diagnosis and treatment of cancer. Kanisa's development strategy combines new treatments for cancer with novel testing formats to stratify patients and predict likely responders to therapy. The company continues to seek late-stage hematology and oncology product licensing opportunities to more fully utilize its infrastructure of very experienced clinical, regulatory, and manufacturing professionals. Kanisa believes that its integrated, targeted approach will maximize treatment benefit to patients, while increasing the efficacy of new and existing drug compounds.
Founded in 1998, Boca Pharmacal's mission is to offer lower-volume items that may have been overlooked by some of the larger generic companies as value-priced alternatives. At Boca Pharmacal, Inc. we strive to provide the highest quality products available in the industry today. We do not plan to bring to market the next blockbuster item coming off patent; but instead, plan to stay focused on delivering niche-type products with excellent customer service. By using sophisticated order entry and tracking systems, our customer service representatives are dedicated to providing a single point of contact to quickly obtain the answers our customers need. Boca Pharmacal, Inc has built a reputation for fast answers, fast resolutions and a friendly voice with all of its customers. Boca Pharmacal, Inc. will continue to focus on research and development of new products, market existing products and offer superior customer service. You are welcome to browse through our website and learn about the different products we offer. If you are interested in obtaining our products, please feel free to e-mail us at info@bocapharmacal.com or call us directly at (800) 354-8460, and we would be more than happy to refer you to one of our many providers.
BIO BALANCE INC., a New York corporation, founded in 1993, is engaged in studies of biomedical problems. The philosophy behind Bio Balance is that accurate descriptions of drug-receptor interactions will lead to the development of better pharmaceuticals. Bio Balance is devoted to a biophysical description of the initial receptor response.
Avantogen Limited is an Australia-based company engaged in the research and development of cancer therapies. The Company is also engaged in virus and vaccine development. The Company is engaged in oncology drug research and development in two geographical segments: Australia and the United States. (Source: ARS)
Collabra was founded to offer pharmaceutical and large biotechnology companies the ability to expand their product development portfolios by developing additional strategically important products without adversely impacting their R&D budget, infrastructure or earnings. Senior management's experience in the industry and ability to bring creative solutions to their partner's strategic needs, and their demonstrated product development capabilities enable Collabra to be a unique and attractive development partner.
DevCo is a virtual pharmaceutical development company focusing on neuroscience. DevCo offers an off income statement funded drug development service to pharmaceutical companies. DevCo identifies, evaluates and acquires licenses to develop compounds in late preclinical or early clinical development. DevCo designs development plans in conjunction with partner pharmaceutical companies and through contractual relationships with Contract Research Organisations (CROs) manages the entire development program. Partner companies retain the rights to market drug candidates. In return, and only if successful, DevCo receives milestone payments and royalties. As a result, DevCo believes that partner companies will be able to exclude certain drug development costs from their income statements and improve short term profitability while retaining the right to market. Following a rigorous evaluation of the drug candidate opportunity, DevCo enters into agreements with partners to undertake, at DevCos cost and risk, the development responsibility for the compound. The development plan is cross functional and may include, but is not limited to, the areas of drug synthesis, toxicology, clinical and regulatory. Development of each compound is carried out by either leading CROs with broad expertise or specialist CROs with specific capabilities in the area of neuroscience clinical development. DevCo retains overall project management responsibility. Partners are not involved in the day to day management of development work but have the right to review and make recommendations on development plans, the design of trial protocols and selection of CROs. DevCos virtual company structure relies heavily on our experienced team of Project Leaders as well as our Project Advisory Board (PAB) comprised of leading scientists with expertise in neuroscience. The PAB assists in the selection and evaluation of new opportunities as well as the ongoing development of existing projects.
Xcelience, with 55 employees today, has operated in the Tampa market since 1997. It was part of the much-larger MDS pharma chain, but broke off to launch the Xcelience brand in May of this year. "I applaud the expansion of Xcelience's state-of-the-art biopharmaceutical laboratory in Tampa. This development will provide a significant contribution to the local economy," said Governor Jeb Bush. "Xcelience and its expanded lab headquarters facilities are an important part of the region's life sciences sector. I thank those who have helped create a business climate that nourishes the growth of companies like Xcelience." Added Tampa Mayor Pam Iorio; "We are thrilled that Xcelience has chosen Tampa to expand their international operations. Their decision indicates Xcelience's confidence in our city's growing biotechnology market." Xcelience's expansion and creation of high-wage jobs in Tampa is a very positive vital sign for Florida's life sciences economy," said EFI President and CEO, John Adams. "High-quality drug development firms, like Xcelience, are critical in growing successful bioscience companies and further diversifying our economy." "We are delighted Xcelience has chosen to expand its already successful Tampa operations", said Jose Valiente, Chair of the Board of the Greater Tampa Chamber of Commerce. "Our burgeoning biotechnology cluster continues to grow everyday." "This is another clear indication of confidence in our county's economic strength," said Jim Norman, Hillsborough County Board of County Commissioners Chair. "We are delighted that Xcelience has committed to expanding its business here in Hillsborough County."
Think of any drug store - from the local neighborhood pharmacy to the major chains - and Clay-Park's products are there. Spanning more than 20 years, Clay-Park Labs, Inc. has a long-standing history of manufacturing high-quality generic topicals that sell to all major trade classes. Clay-Park's commitment to discover first-to-market, Rx, OTC and cosmetic products is unsurpassed. Topicals for Today & Tomorrow is the trademark of Clay-Park Labs, Inc. A fully owned subsidiary of Agis (established in 1983), Clay-Park is part of an intricate international organization. It is an organization dedicated to R&D and exemplifies dependable APIs to focus on topicals that encompass many forms of dermatological products (creams, ointments, lotions, gels, solutions, suppositories and unit dose). The pipeline also contains delivery systems including nasal sprays, foams, transdermal hormones and various other types of products that expand the breadth of Clay-Park's offerings. Maintaining a self-imposed standard of supplying quality products at high service levels, the 350,000 square foot facility located in New York accommodates close to 500 employees and fully complies with strict cGMP standards and FDA regulations and inspections. With an Rx product portfolio of over 65 SKUs and an OTC/cosmetic product portfolio of over 100 SKUs, Clay-Park continually adheres to rigorous quality assurance standards and utilizes their modern facilities to meet the growing demands of the competitive generic marketplace. Clay-Park continues to increase sales and distribution through its strong track record of new approved ANDAs and enhance the pharmaceutical and OTC benefits to pharmacists, physicians and patients. Clay-Park welcomes all comments and suggestions.
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory